Navigation Links
Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
Date:12/10/2010

THOUSAND OAKS, Calif., Dec. 10, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced results from new analyses comparing XGEVA™ (denosumab), the first new treatment for advanced cancer patients with bone metastases in nearly a decade to prevent skeletal-related events, to Zometa® (zoledronic acid). These results underscore the efficacy profile of XGEVA in preventing skeletal-related events (SREs) in patients with bone metastases from advanced breast cancer, as well as explore XGEVA's impact on pain and quality of life outcomes, compared to Zometa. These new results were presented at the 33rd Annual San Antonio Breast Cancer Symposium.

XGEVA was approved on Nov. 18, 2010 by the U.S. Food and Drug Administration (FDA) after a priority review, a designation reserved for drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. XGEVA is indicated for the prevention of SREs in patients with bone metastases from solid tumors. XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma.

New Extended Treatment Phase Data from Pivotal Phase 3 Study "136" Demonstrates Continued Superiority of XGEVA Compared to Zometa (Abstract Number: P6-14-01)San Antonio Sponsored Press Briefing, Dec. 10, 2010 at 12:30 p.m. CT

An additional four months of double-blinded treatment data from the pivotal Phase 3 "136" study was presented in a press briefing at SABCS today. The data showed that XGEVA was superior to Zometa in delaying the time to first on-study SRE by 18 percent and time to first-and-subsequent on-study event by 22 percent.  Further, the median time to first on-study SRE was five months longer for the patients at risk in the XGEVA group (32.4 months) versus the Zometa group (27.4 months) in patients with advanced breast cancer and bone metastases HR 0.82 (95 percent C
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Amgen to Present at Deutsche Banks 2010 BioFEST
2. Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
3. Amgen Foundation and Ashokas Changemakers Announce Finalists in Patients
4. Choices
5. Empowerment Competition
6. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
7. Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LAs Promise
8. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
9. Amgen Announces Webcast of 2010 Third Quarter Financial Results
10. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
11. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... and PARIS , May ... ), a leading developer and manufacturer of precision guided ... of coronary and peripheral vascular disease, today announced preliminary ... asodilator I ndependent S tenosis E ... clinical trial session at EuroPCR 2013. These prospective results ...
(Date:5/23/2013)... , 22. Mai 2013 ... eine Tochtergesellschaft von Daiichi Sankyo Co., ... am 22. Mai die Maßnahmen bekannt, ... ergriffen hat, um sich der Angelegenheiten ... ( http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html ). Daiichi ...
(Date:5/22/2013)... HILLS, Calif. , May 22, 2013 ... developing a medical device that will help alleviate the ... APT,s targeted apheresis cartridge is expected to be the ... leading cause of maternal and fetal death. ... the United States . It is ...
Breaking Medicine Technology:Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an 2Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia 2
(Date:5/23/2013)... (PRWEB) May 23, 2013 During pregnancy ... fetus are affected by medical treatments, especially medication. ... England Journal of Medicine prompted the FDA to warn ... serious birth defects such as persistent pulmonary hypertension and ... selective serotonin reuptake inhibitor (SSRI) drugs. SSRI antidepressants ...
(Date:5/23/2013)... AZ (PRWEB) May 23, 2013 Looking for ... dealing with the sensitive issue of caring for your aging ... Geriatric Care Managers (NAPGCM) released the results of a ... this question. , Here are the top ... (along with the percentage of survey respondents selecting each option): ...
(Date:5/23/2013)... Madrid, 23 May 2013.- CNIC researchers have discovered that ... the release of hematopoietic stem cells from the bone ... today in the journal Cell ., Neutrophils are ... attack from bacteria and other disease organisms. To perform ... come into contact with microorganisms. However, release of these ...
(Date:5/23/2013)... May 23, 2013 A medical Internet ... Surge, LLC. Targeting members of the medical and healthcare ... attract new patients, the consulting service is focused on ... , The medical Internet marketing agency is providing the ... results online. As part of the consulting, the company ...
(Date:5/23/2013)... 23, 2013 Wei Angela Liu, MD, ... Memorial Hospital Center as Medical Director of Physical ... inpatient and outpatient rehabilitation care to patients of all ... her undergraduate degree in biochemistry at Columbia College, honored ... She earned her medical degree at New York University ...
Breaking Medicine News(10 mins):Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 2Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 3Health News:New Survey of Aging Experts Gives Top 5 Tips for Avoiding Family Feud when Caring for Aging Parents 2Health News:Discarded immune cells induce the relocation of stem cells 2Health News:Healthcare Internet Marketing Consulting Services Launched by JD Media Surge 2Health News:Wei Angela Liu, MD, Named Head of Physical Medicine and Rehabilitation at Phelps Memorial Hospital Center in Sleepy Hollow, New York 2
... ... , ... 24, 2010 -- At just over 18 pounds and with a sound level of only ... lighter and quieter than its battery-operated competitors. Powered by a lithium ion battery with 30 ...
... halt, expert says , TUESDAY, March 23 (HealthDay News) ... trials that are stopped early due to encouraging results, ... of 91 truncated trials with 424 comparable full-length trials, ... in particular, smaller studies -- reported exaggerated or misleading ...
... Walking, biking, dancing can all help normal-weight women as they ... An hour a day of moderate-intensity exercise will prevent weight ... a new study. , ",Moderate intensity, means brisk walking, casual ... Lee, lead author of the study, which is published in ...
... , BOSTON , March 23 ... current ESPN analyst Tedy Bruschi ... Trustees of Partners Continuing Care, the non-acute division of ... Partners Home Care, Partners Continuing Care offers the full ...
... America today hailed the "Patient Protection and Affordable Care Act" signed by the President today. The legislation will greatly expand access to mental health care ... ... , , ... ...
... , March 23 The Alzheimer,s Foundation of America issued the following statement on the health reform legislation that was signed into law today by President Obama:   , ... , ... ... ...
Cached Medicine News:Health News:Advance Introduces the Adgility™ XPB Battery Backpack Vacuum – the Lightest in the Industry, 2Health News:Abbreviated Trials Yield Misleading Results: Study 2Health News:Being Active an Hour a Day Puts Brakes on Weight Gain 2Health News:Being Active an Hour a Day Puts Brakes on Weight Gain 3Health News:Tedy Bruschi Joins the Board of Trustees for Partners Continuing Care and Spaulding Rehabilitation Network 2Health News:Tedy Bruschi Joins the Board of Trustees for Partners Continuing Care and Spaulding Rehabilitation Network 3Health News:Mental Health America Hails Enactment of Historic Health Care Reform Bill 2Health News:Mental Health America Hails Enactment of Historic Health Care Reform Bill 3Health News:Alzheimer's Foundation of America Hails Significant Provisions for Dementia Community in Health Reform Law 2Health News:Alzheimer's Foundation of America Hails Significant Provisions for Dementia Community in Health Reform Law 3Health News:Alzheimer's Foundation of America Hails Significant Provisions for Dementia Community in Health Reform Law 4
The Clark Socket fits all American-made tables with standard 3/8"W x 1 1/8" H siderails. Fits round mounting posts up to 11/16" in diameter....
Inquire...
Stainless steel construction to withstand sterilization modalities (EtO, Steris, and Sterrad) Wide angle of view...
Inquire...
Medicine Products: